HighTower Advisors LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,302 shares of the biopharmaceutical company's stock after selling 2,723 shares during the period. HighTower Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $21,585,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $28,000. Private Wealth Management Group LLC increased its stake in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 39 shares during the period. Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $49,000. Institutional investors and hedge funds own 83.31% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently commented on REGN. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. Bernstein Bank decreased their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Bank of America reaffirmed an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Finally, BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $973.13.
Read Our Latest Stock Report on REGN
Regeneron Pharmaceuticals Stock Up 1.1 %
Shares of Regeneron Pharmaceuticals stock traded up $7.40 during trading on Wednesday, reaching $672.36. The stock had a trading volume of 674,993 shares, compared to its average volume of 626,763. The company has a market capitalization of $73.51 billion, a price-to-earnings ratio of 17.56, a P/E/G ratio of 2.34 and a beta of 0.27. The stock has a fifty day moving average price of $692.84 and a two-hundred day moving average price of $823.99. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 earnings per share. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. Regeneron Pharmaceuticals's payout ratio is presently 2.30%.
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Articles
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
